(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 16 December 2004 (16.12.2004)

PCT

(10) International Publication Number WO 2004/109286 A3

- (51) International Patent Classification⁷: Go 33/68, C12Q 1/68, C07K 16/28
- G01N 33/574,
- (21) International Application Number:

PCT/CA2004/000857

- (22) International Filing Date: 9 June 2004 (09.06.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:

60/476,622 9 June 2003 (09.06.2003) US 60/537,018 20 January 2004 (20.01.2004) US

- (71) Applicant (for all designated States except US): THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; #103-6190 Agronomy Road, Vancouver, British Columbia V6T 1Z3 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MCNAGNY, Kelly, M. [US/CA]; 4725 Blenheim Street, Vancouver, British Columbia V6L 3A5 (CA). ROSKELLEY, Calvin [CA/CA]; 5609 Kings Road, Vancouver, British Columbia V6T 1Z3 (CA). MERKENS, Helen [CA/CA]; 8463-12th Avenue, Burnaby, British Columbia V3N 2L8 (CA). SOMASIRI, Aruna [CA/CA]; #487, 6335 Thunderbird Cres., Vancouver, British Columbia V6T 2G9 (CA). HUNTSMAN, David [CA/CA]; 3622 West 18th Avenue, Vancouver, British Columbia V6S 1B2 (CA).

- (74) Agent: BERESKIN & PARR; 40 King Street West, Suite 4000, Toronto, Ontario M5H 3Y2 (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 21 April 2005


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR DETECTING AND TREATING CANCER USING PODOCALYXIN AND/OR ENDOGLYCAN

The anti-mEndoglycan Antibody is Specific for Endoglycan








Relative Fluorescence Intensity (log10)

(57) Abstract: Methods and kits for detecting cancer and monitoring cancer progression are described. The method involves analyzing a sample containing nucleic acids or proteins from a patient for decreased expression of endoglycan and/or increased expression of podocalyxin.

Internal Application No PC1/CA2004/000857

A. CLASSIF IPC 7	FICATION OF SUBJECT MATTER G01N33/574 G01N33/68 C12Q1/6	8 C07K16/28	
	International Patent Classification (IPC) or to both national classific	cation and IPC	
Minimum do	SEARCHED cumentation searched (classification system followed by classification	tion symbols)	
IPC 7	GO1N C12Q C07K		
Documentat	ion searched other than minimum documentation to the extent that	such documents are included in the fields se	arched
	ata base consulted during the international search (name of data b)
EPO-In	ternal, WPI Data, PAJ, BIOSIS, EMBA	SE, Sequence Search	
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.
		-/	
		,	
X Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.
° Special ca	ategories of cited documents:	"T" later document published after the inte or priority date and not in conflict with	ernational filing date
consid	ent defining the general state of the art which is not dered to be of particular relevance	cited to understand the principle or th invention	eory underlying the
filing o	document but published on or after the international date ent which may throw doubts on priority claim(s) or	"X" document of particular relevance; the cannot be considered novel or canno involve an inventive step when the do	t be considered to
which citatio	is cited to establish the publication date of another on or other special reason (as specified)	"Y" document of particular relevance; the cannot be considered to involve an in	claimed invention eventive step when the
other	nent referring to an oral disclosure, use, exhibition or means	document is combined with one or moments, such combination being obvious in the art.	
later t	ent published prior to the international filing date but han the priority date claimed	*&* document member of the same patent	
Date of the	actual completion of the international search	Date of mailing of the international sea	исп героп
1	9 January 2005	15/02/2005	
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Giry, M	



C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/079492 A (EOS BIOTECHNOLOGY, INC.) 10 October 2002 (2002-10-10) page 1, line 15 - page 5, line 15 page 15 page 17, line 25 - page 19, line 5 page 21, line 5 - line 35 page 30, line 30 - page 33, line 25 page 43, line 25 - line 35 page 45, line 9 - page 46, line 35 page 49, line 10 - page 50, line 25 page 51, line 17 - page 54, line 35 page 58, line 3 page 59, line 21 - page 63, line 6 page 65, line 10 - page 67, line 25 page 70, line 5 - page 73, line 10 page 76, line 25 - page 77, line 15 Table 3 (p. 121 and p. 124) Table 4 (p. 151 and p. 154) Table 7 (p. 177) SEQ ID NO:13 and SEQ ID NO:14 (100% identical to SEQ ID NO:1 in the application; endoglycan)	1-33
Υ	US 6 395 882 B1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 28 May 2002 (2002-05-28) column 1 - column 2 column 13, line 55 - column 14, line 45 column 15, line 45 - column 18, line 5 column 20, line 5 - column 21, line 55 column 23, line 45 - column 24, line 5	14-16 1-4, 6-13, 17-22, 24-33
	column 26, paragraph F column 30, paragraph A column 31, paragraph B	
Y	SCHOPPERLE W.M. ET AL.: "Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin." BIOCHEM. BIOPHYS. RES. COMMUN., vol. 300, no. 2, 10 January 2003 (2003-01-10), pages 285-290, XP002314244 cited in the application abstract page 285, paragraph 1 - page 286, paragraph 2	1-4, 6-22, 24-33



	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Delevent to delen Ma
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FIEGER C.B. ET AL.: "Endoglycan, a member of the CD34 family, functions as an L-selectin ligand through modification with tyrosine sulfation and sialyl Lewis x." J. BIOL. CHEM., vol. 278, no. 30, 16 May 2003 (2003-05-16), pages 27390-27398, XP002314245 cited in the application the whole document	1-4, 6-22, 24-33
T	SOMASIRI A. ET AL.: "Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression." CANCER RES., vol. 64, 1 August 2004 (2004-08-01), pages 5068-5073, XP002314246 the whole document	1-33

ппогтацоп он расенстанну шениегь



					,	
Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 02079492	Α	10-10-2002	CA	2438030	A1	10-10-2002
10 020/3 132	,,	#0 #0 E00E	EP	1418943		19-05-2004
			JΡ		T	14-10-2004
			WO	02079492		10-10-2002
			ÜS	2003152926		14-08-2003
			US	2004009494		15-01-2004
			US	2004259152		23-12-2004
			US	2004033495	A1	19-02-2004
			CA	2444691	A1	31-10-2002
			CA	2451465	A1	27-12-2002
			CA	2453098	A1	16-01-2003
			CA	2459219	A1	27-03-2003
			CA	2467433	A1	22-05-2003
			EP	1463928	A2	06-10-2004
			EP	1408811	A2	21-04-2004
			EP	1434881		07-07-2004
			EP	1497454	A2	19-01-2005
			WO	02086443	A2	31-10-2002
			WO	02098358		12-12-2002
			WO	02102235		27-12-2002
			WO	03003906		16-01-2003
			WO	03025138		27-03-2003
			WO	03042661		22-05-2003
			US	2004005563		08-01-2004
			US	2004076955		22-04-2004
			US	2003124579		03-07-2003
			US	2003232350	A1	18-12-2003
US 6395882	B1	28-05-2002	US	2002025923	A1	28-02-2002
			ΑÜ	2477199		30-08-1999
			CA	2318068		19-08-1999
			EP	1053307		22-11-2000
			JP		T	05-03-2002
			WO	9941363	A1	19-08-1999
						30-04-2002